KR20080064169A - 암의 초기 ｍｒｉ 검출을 개선하기 위한 종양-표적화나노전달 시스템 - Google Patents

암의 초기 ｍｒｉ 검출을 개선하기 위한 종양-표적화나노전달 시스템 Download PDF

Info

Publication number
KR20080064169A
KR20080064169A KR1020087011910A KR20087011910A KR20080064169A KR 20080064169 A KR20080064169 A KR 20080064169A KR 1020087011910 A KR1020087011910 A KR 1020087011910A KR 20087011910 A KR20087011910 A KR 20087011910A KR 20080064169 A KR20080064169 A KR 20080064169A
Authority
KR
South Korea
Prior art keywords
cationic
imaging
administration
complex
imaging agent
Prior art date
Application number
KR1020087011910A
Other languages
English (en)
Korean (ko)
Inventor
에스터 에이치. 장
카트린 에프. 피롤로
Original Assignee
조지타운 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 조지타운 유니버시티 filed Critical 조지타운 유니버시티
Publication of KR20080064169A publication Critical patent/KR20080064169A/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461—Dispersions, colloids, emulsions or suspensions
    • A61K49/0466—Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020087011910A 2005-10-20 2006-10-20 암의 초기 ｍｒｉ 검출을 개선하기 위한 종양-표적화나노전달 시스템 KR20080064169A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72830305P 2005-10-20 2005-10-20
US60/728,303 2005-10-20

Publications (1)

Publication Number Publication Date
KR20080064169A true KR20080064169A (ko) 2008-07-08

Family

ID=37963345

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087011910A KR20080064169A (ko) 2005-10-20 2006-10-20 암의 초기 ｍｒｉ 검출을 개선하기 위한 종양-표적화나노전달 시스템

Country Status (8)

Country Link
JP (1) JP5478886B2 (xx)
KR (1) KR20080064169A (xx)
CN (1) CN101351225B (xx)
AU (1) AU2006304790B2 (xx)
CA (1) CA2638899C (xx)
HK (1) HK1129063A1 (xx)
IL (1) IL190773A (xx)
WO (1) WO2007047981A2 (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101570886B1 (ko) * 2007-07-09 2015-11-23 조지타운 유니버시티 양이온성-리포솜 매개된 핵산 전달을 이용하여 면역 반응을 생성시키는 방법
US8320647B2 (en) 2007-11-20 2012-11-27 Olea Medical Method and system for processing multiple series of biological images obtained from a patient
WO2010054401A1 (en) * 2008-11-10 2010-05-14 Alnylam Pharmaceuticals, Inc. Novel lipids and compositions for the delivery of therapeutics
CN102078624B (zh) * 2010-12-23 2012-07-25 华东理工大学 一种高效载钆脂质体制剂及其制备方法
WO2013031619A1 (ja) * 2011-08-26 2013-03-07 学校法人藤田学園 抗ヒトトランスフェリン受容体抗体を含む画像用腫瘍診断剤
US20140120157A1 (en) 2012-09-19 2014-05-01 Georgetown University Targeted liposomes
AU2013200991B2 (en) * 2012-09-19 2015-12-10 Georgetown University Targeted liposomes
CN105163762B (zh) * 2013-03-14 2019-06-25 乔治敦大学 对神经毒剂的暴露的治疗
US20210077399A1 (en) * 2018-05-08 2021-03-18 University Of Florida Research Foundation, Incorporated Magnetic liposomes and related treatment and imaging methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040049A2 (de) * 1997-03-07 1998-09-17 Max-Delbrück-Centrum für Molekulare Medizin Spezifische magnetosomen, verfahren zu ihrer herstellung und ihre verwendung
CA2362550C (en) * 1999-02-22 2010-05-11 Georgetown University Antibody fragment-targeted immunoliposomes for systemic gene delivery
US7780882B2 (en) * 1999-02-22 2010-08-24 Georgetown University Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent
HUP0301835A2 (hu) * 2000-05-03 2003-09-29 Mbt Munich Biotechnology Ag Kationos diagnosztikai, képalkotó és terápiás ágensek, aktivált vaszkuláris helyekkel asszociálódva
WO2003084386A2 (en) * 2002-04-03 2003-10-16 See Jackie R Methods for ultrasonic imaging and treating diseased tissues
CA2513769A1 (en) * 2003-01-28 2004-08-12 Georgetown University Method for evaluating the efficacy of certain cancer treatments
US20050002998A1 (en) * 2003-06-04 2005-01-06 Georgetown University Method for improving stability and shelf-life of liposome complexes
CA2530224A1 (en) * 2003-07-09 2005-02-24 California Pacific Medical Center Remote detection of substance delivery to cells
JP2005170807A (ja) * 2003-12-09 2005-06-30 Fuji Photo Film Co Ltd 抗体を含むリポソーム

Also Published As

Publication number Publication date
CN101351225B (zh) 2013-09-25
WO2007047981A3 (en) 2007-10-25
JP2009512712A (ja) 2009-03-26
IL190773A0 (en) 2008-11-03
WO2007047981A2 (en) 2007-04-26
AU2006304790B2 (en) 2013-06-27
AU2006304790A1 (en) 2007-04-26
JP5478886B2 (ja) 2014-04-23
IL190773A (en) 2012-06-28
CN101351225A (zh) 2009-01-21
CA2638899C (en) 2016-01-05
HK1129063A1 (en) 2009-11-20
CA2638899A1 (en) 2007-04-26

Similar Documents

Publication Publication Date Title
US8617514B2 (en) Tumor-targeted nanodelivery systems to improve early MRI detection of cancer
ElBayoumi et al. Current trends in liposome research
AU2006304790B2 (en) Tumor-targeted nanodelivery systems to improve early MRI detection of cancer
Sonju et al. Peptide-functionalized liposomes as therapeutic and diagnostic tools for cancer treatment
Schnyder et al. Drug transport to brain with targeted liposomes
Mulder et al. Lipid‐based nanoparticles for contrast‐enhanced MRI and molecular imaging
US9801943B2 (en) Method for in vivo targeting of nanoparticles via bioorthogonal copper-free click chemistry
Torchilin Multifunctional and stimuli-sensitive pharmaceutical nanocarriers
EP2215107B1 (en) Peptide ligand directed drug delivery
Torchilin Multifunctional pharmaceutical nanocarriers: development of the concept
JP4987474B2 (ja) リポソーム複合体の安定性および使用期限を改良するための方法
US20130243867A1 (en) Micelle compositions and methods for their use
JP2004535407A (ja) 標的化多価高分子
Guo et al. New FH peptide-modified ultrasonic nanobubbles for delivery of doxorubicin to cancer-associated fibroblasts
Khera et al. Highlighting the potential role of exosomes as the targeted nanotherapeutic carrier in metastatic breast cancer
KR101979497B1 (ko) 양자점-핵산-앱타머-리포좀 복합체, 이의 용도 및 이의 제조방법
EP3402484B1 (en) Peptide-conjugated nanoparticles for targeting, imaging, and treatment of prostate cancer
Su et al. In vivo magnetic resonance and fluorescence dual-modality imaging of tumor angiogenesis in rats using GEBP11 peptide targeted magnetic nanoparticles
Hirai et al. E‐selectin targeting to visualize tumorsin vivo
Karpuz et al. Nanovesicles for tumor-targeted drug delivery
US20230067643A1 (en) Iron oxide nanoparticle for targeted chemo-immunotherapy
Juul et al. HER2-targeted, enzyme-activated liposomes show superior in vivo efficacy in an ovarian cancer model
Meenu Polymeric and inorganic nanoparticles for cancer treatment and diagnosis
KR20230095864A (ko) 약물전달입자의 엔도좀 탈출 효율 분석 방법
Kozlowska Application of targeted contrast nanoparticles for human multiple myeloma imaging

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application